HRP20110242T1 - Formulacija s fuzijskim proteinom glp-1-fc - Google Patents

Formulacija s fuzijskim proteinom glp-1-fc Download PDF

Info

Publication number
HRP20110242T1
HRP20110242T1 HR20110242T HRP20110242T HRP20110242T1 HR P20110242 T1 HRP20110242 T1 HR P20110242T1 HR 20110242 T HR20110242 T HR 20110242T HR P20110242 T HRP20110242 T HR P20110242T HR P20110242 T1 HRP20110242 T1 HR P20110242T1
Authority
HR
Croatia
Prior art keywords
stable solution
formulation according
solution formulation
concentration
glp
Prior art date
Application number
HR20110242T
Other languages
English (en)
Croatian (hr)
Inventor
Ng Kingman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39870243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20110242T1 publication Critical patent/HRP20110242T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20110242T 2007-07-10 2008-07-09 Formulacija s fuzijskim proteinom glp-1-fc HRP20110242T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94885507P 2007-07-10 2007-07-10
PCT/US2008/069473 WO2009009562A2 (en) 2007-07-10 2008-07-09 Glp-1-fc fusion protein formulation

Publications (1)

Publication Number Publication Date
HRP20110242T1 true HRP20110242T1 (hr) 2011-05-31

Family

ID=39870243

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110242T HRP20110242T1 (hr) 2007-07-10 2008-07-09 Formulacija s fuzijskim proteinom glp-1-fc

Country Status (18)

Country Link
US (1) US20100196405A1 (de)
EP (1) EP2175834B8 (de)
JP (1) JP2010533197A (de)
KR (1) KR20100020516A (de)
CN (1) CN101730523A (de)
AT (1) ATE499088T1 (de)
AU (1) AU2008275180A1 (de)
BR (1) BRPI0813699B1 (de)
CA (1) CA2691695C (de)
DE (1) DE602008005155D1 (de)
EA (1) EA201070121A1 (de)
HR (1) HRP20110242T1 (de)
MX (1) MX2010000380A (de)
NZ (1) NZ582480A (de)
RS (1) RS52378B (de)
UA (1) UA97673C2 (de)
WO (1) WO2009009562A2 (de)
ZA (1) ZA201000149B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107412737A (zh) * 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
WO2014014206A1 (en) * 2012-07-20 2014-01-23 University-Industry Cooperation Group Of Kyung Hee University Novel peptide tag and uses thereof
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PE20151421A1 (es) * 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN104173275A (zh) * 2013-05-21 2014-12-03 深圳翰宇药业股份有限公司 度拉鲁肽注射剂及其制备方法
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PL3257524T3 (pl) * 2015-02-11 2021-03-08 Gmax Biopharm Llc Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN107661288A (zh) * 2016-07-29 2018-02-06 江苏泰康生物医药有限公司 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
CN107698684B (zh) * 2016-08-03 2021-09-28 广东东阳光药业有限公司 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白
CN108210890A (zh) * 2016-12-09 2018-06-29 江苏泰康生物医药有限公司 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド
BR112020002871A2 (pt) * 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
MX2020005231A (es) * 2017-11-21 2020-08-24 Lilly Co Eli Metodos de uso y composiciones que contienen dulaglutida.
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020190591A1 (en) 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
CN114053217B (zh) * 2020-08-03 2023-04-18 华兰生物工程股份有限公司 一种Exendin-4-Fc融合蛋白注射制剂及其制备方法
CN112494658B (zh) * 2020-12-04 2024-07-12 苏州药明生物技术有限公司 一种稳定的Fc融合蛋白制剂
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
TW202317607A (zh) 2021-07-06 2023-05-01 大陸商蘇州康寧杰瑞生物科技有限公司 融合蛋白及其應用
WO2024197132A1 (en) 2023-03-23 2024-09-26 Eli Lilly And Company Methods of producing fc-containing proteins
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025122835A2 (en) 2023-12-08 2025-06-12 Eli Lilly And Company Methods of producing fc-containing proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011166B1 (ru) * 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1

Also Published As

Publication number Publication date
DE602008005155D1 (de) 2011-04-07
CA2691695A1 (en) 2009-01-15
CA2691695C (en) 2014-03-18
MX2010000380A (es) 2010-03-29
WO2009009562A2 (en) 2009-01-15
JP2010533197A (ja) 2010-10-21
EP2175834B8 (de) 2012-08-22
BRPI0813699A2 (pt) 2014-12-30
AU2008275180A1 (en) 2009-01-15
US20100196405A1 (en) 2010-08-05
KR20100020516A (ko) 2010-02-22
EA201070121A1 (ru) 2010-06-30
EP2175834B1 (de) 2011-02-23
WO2009009562A3 (en) 2009-07-09
ATE499088T1 (de) 2011-03-15
UA97673C2 (ru) 2012-03-12
CN101730523A (zh) 2010-06-09
HK1141237A1 (en) 2010-11-05
EP2175834A2 (de) 2010-04-21
ZA201000149B (en) 2011-04-28
BRPI0813699B1 (pt) 2021-06-22
RS52378B (sr) 2012-12-31
NZ582480A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
AR069989A1 (es) Formulaciones de vwf recombinantes
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2012106150A (ru) Вариантные формы уратоксидазы и их применение
NZ591497A (en) A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
RU2009116531A (ru) Способ лечения остеопороза и используемая в нем композиция
JP2009530395A5 (de)
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
PE20071063A1 (es) Formulaciones de proteinas estables
HRP20140616T1 (hr) Peptidni analog oksintomodulina
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
ES2689781T3 (es) Angiotensina en el tratamiento de afecciones cerebrales
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
RU2008141280A (ru) Агонисты рецептора нейромедина u и их применение
JP2012523438A5 (de)
JP2007523881A5 (de)
EP1626055A3 (de) Nicht von Säugetieren stammende GnRH Analoga und deren Verwendung zur Regulierung des Immunsystems
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
JP2005530732A5 (de)
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
RU2017101667A (ru) Фармацевтические композиции
RU2011101391A (ru) Ингибиторы пептидиларгининдезиминазы (pad)
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
WO2022177878A1 (en) Glucagon-like peptide-1 receptor antagonists